Oramed Pharmaceuticals Inc (ORMP)

8.16
0.06 0.73
NASDAQ : Health Care
Prev Close 8.22
Open 8.20
Day Low/High 8.03 / 8.22
52 Wk Low/High 4.15 / 10.74
Volume 8.22K
Avg Volume 34.30K
Exchange NASDAQ
Shares Outstanding 13.32M
Market Cap 108.03M
EPS -0.90
P/E Ratio 9.32
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

3 Stocks Under $10 Triggering Breakout Trades

3 Stocks Under $10 Triggering Breakout Trades

These under-$10 stocks are within range of triggering big breakout trades.

A Speculative Biotech Catalyst Trade: ORMP

A Speculative Biotech Catalyst Trade: ORMP

This beaten-down biotech stock could be ripe for a rebound.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Oramed's Oral Insulin Pill Data 'Completely Worthless'

Oramed's Oral Insulin Pill Data 'Completely Worthless'

Oramed hyped results from an insulin pill safety study, then made it difficult to find the actual data.

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013. Here are the charts:

[video] Quick Take: Revolutionizing Diabetes Treatment

[video] Quick Take: Revolutionizing Diabetes Treatment

This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.

Seeking to Remake Diabetes Therapy

Seeking to Remake Diabetes Therapy

This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.

Oramed Pharmaceuticals Granted Israeli Patent For Its Core Technology In Oral Delivery Of Proteins

Oramed Pharmaceuticals Granted Israeli Patent For Its Core Technology In Oral Delivery Of Proteins

Marking a major milestone for the company, Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Awarded Grant By The Office Of The Chief Scientist Of Israel

Oramed Pharmaceuticals Awarded Grant By The Office Of The Chief Scientist Of Israel

Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( http://www.